share, authorized 90,000,000 shares,
issued 36,460,461 and 35,901,276
shares 364 359
Additional paid-in-capital 274,963 254,013
Retained earnings 230,195 180,298
Accumulated other comprehensive
loss (1,362) (431)
Treasury stock, at cost 2,604,977
and 889,245 shares (66,405) (33,188)
Total stockholders' equity 437,755 401,051
Total liabilities and stockholders'
equity $781,523 $814,677
PAR PHARMACEUTICAL COMPANIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Data)
(Unaudited)
Three months ended Twelve months ended
December 31, December 31, December 31, December 31,
2007 2006 2007 2006
Revenues:
Net product sales $149,494 $176,807 $739,020 $705,378
Other product
related revenues 5,646 6,826 30,646 19,790
Total revenues 155,140 183,633 769,666 725,168
Cost of goods sold 97,293 124,680 501,147 507,220
Gross margin 57,847 58,953 268,519 217,948
Operating expenses:
Research and
development 16,528 18,459 77,659 62,442
Selling, general and
administrative 37,751 37,152 138,217 148,488
Intangible assets
impairment - 1,100 - 1,100
Settlements, net - - (945) 1,
'/>"/>
| SOURCE Par Pharmaceutical Companies, Inc. Copyright©2008 PR Newswire. All rights reserved |